| 101167-5 |
Metonitazene/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Metonitazene/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
101167-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Metonitazene/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mg{creat} |
|
|
|
0 |
| 101168-3 |
Metonitazene |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
Metonitazene [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101168-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Metonitazene Ur Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101169-1 |
2-Methyl AP-237 |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
2-methyl AP-237 [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101169-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2-methyl AP-237 Ur Cfm-mCnc |
|
|
|
N |
|
2-methyl Bucinnazine; Anterio-Posterior; Anteroposterior; CAS 98608-61-8; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; hydrochloride salt 98608-59-4; II; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 10117-0 |
ST wave displacement.end.lead V6 |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
ST wave end displacement in lead V6 |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10117-0 |
|
EKG |
|
|
Observation |
|
|
|
0 |
ST wave ED L-V6 |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave ED L-V6; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101170-9 |
Soluble urokinase plasminogen activator receptor |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Soluble urokinase plasminogen activator receptor [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
CHEM |
|
101170-9 |
|
|
|
|
Both |
|
|
|
0 |
suPAR SerPl-mCnc |
|
|
|
N |
|
Chemistry; Level; Mass concentration; Pl; Plasma; PLG; PLGN; Plsm; Point in time; Profibrinolysin; QNT; Quan; Quant; Quantitative; Random; Rec; Recept; Receptors; Recp; Recptr; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; suPAR |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101171-7 |
2-Methyl AP-237/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
2-methyl AP-237/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
101171-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2-methyl AP-237/Creat Ur Cfm |
|
|
|
N |
|
2-methyl Bucinnazine; Anterio-Posterior; Anteroposterior; CAS 98608-61-8; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; hydrochloride salt 98608-59-4; II; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mg{creat} |
|
|
|
0 |
| 101172-5 |
Chlamydia trachomatis & Neisseria gonorrhoeae & Trichomonas vaginalis rRNA panel |
- |
XXX |
Pt |
- |
Probe.amp.tar |
|
ACTIVE |
Chlamydia trachomatis and Neisseria gonorrhoeae and Trichomonas vaginalis rRNA panel - Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.MICRO |
|
101172-5 |
|
Probe.amp.tar |
|
|
Order |
|
|
|
0 |
CT + NG + TV rRNA Pnl Spec NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; C trac; C trach; C trach+GC; C tracho; C trachomatis; Chlam; Chlam trac; Chlamid; CT; CT + NG + TV; CT + NG + TV rRNA Pnl; CT/GC; DNA NUCLEIC ACID PROBE; DNA probe; GC; Gen-Probe; Gono; Gonorrhea; LAT; LCR; LGV; Ligase chain reaction; Ligation-activated transcription; Lymphogranuloma venereum; Microbiology; Misc; Miscellaneous; N gonorrhoea; N gonorrhoeae; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Other; Pan; PANEL.MICROBIOLOGY; Panl; PCR; Pnl; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; Random; ribosomal RNA; SDA; Spec; Strand Displacement Amplification; T vaginalis; TMA; To be specified in another part of the message; Trachoma; Transcription mediated amplification; Tric; Trich; Trichimoniasis; Trichomonad; Trichomonads; Trichomoniasis; Unspecified |
2.75 |
2.74 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
| 101173-3 |
Melatonin |
SCnc |
Saliva |
Pt |
Qn |
|
|
ACTIVE |
Melatonin [Moles/volume] in Saliva (oral fluid) |
|
MIN |
DefinitionDescription |
|
|
pmol/L |
|
|
|
|
|
|
CHEM |
|
101173-3 |
|
|
|
|
Both |
|
|
|
0 |
Melatonin Sal-sCnc |
|
|
|
N |
|
Chemistry; Level; Oral fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; Sal; Substance concentration |
2.75 |
2.74 |
|
|
|
|
|
|
|
pmol/L |
|
|
|
0 |
| 101174-1 |
17-Hydroxyprogesterone |
MCnc |
Saliva |
Pt |
Qn |
|
|
ACTIVE |
17-Hydroxyprogesterone [Mass/volume] in Saliva (oral fluid) |
|
MIN |
DefinitionDescription |
|
|
pg/mL |
|
|
|
|
|
|
CHEM |
|
101174-1 |
|
|
|
|
Both |
|
|
|
0 |
17OHP Sal-mCnc |
|
|
|
N |
|
17-alpha-hydroxyprogesterone; 17-Hydroxypregn-4-en-3,20-dione; 17-hydroxy-progest; 17-OH Progesterone; 17OHP; 17-OHP; 17-P; Chemistry; Hydroxyproges; Hydroxyprogstron; Level; Mass concentration; Oral fluid; Point in time; QNT; Quan; Quant; Quantitative; Random; Sal |
2.75 |
2.74 |
|
|
|
|
|
|
|
pg/mL |
|
|
|
0 |
| 101175-8 |
3-Methoxytyramine.free/Creatinine |
SRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
3-Methoxytyramine.free/Creatinine [Molar ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/mol |
|
|
|
|
|
|
CHEM |
|
101175-8 |
|
|
|
|
Both |
|
|
|
0 |
Free 3-MT/Creat SerPl-sRto |
|
|
|
N |
|
3Me-tyramine; Chemistry; CR; Crea; Creat; Dopamine metabolite; FR; Free 3-MT; III; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration ratio; Substance ratio |
2.75 |
2.74 |
|
|
|
|
|
|
|
umol/mol |
|
|
|
0 |
| 101176-6 |
Normetanephrine.free/Creatinine |
SRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Normetanephrine Free/Creatinine [Molar ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/mol |
|
|
|
|
|
|
CHEM |
|
101176-6 |
|
|
|
|
Both |
|
|
|
0 |
Normetaneph Free/Creat SerPl-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; FR; Non-protein bound; Normeta; Normetaneph; Normetaneph Free; Normetanephrn; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration ratio; Substance ratio; Unconjugated normetanephrine |
2.75 |
2.74 |
|
|
|
|
|
|
|
umol/mol |
|
|
|
0 |
| 101177-4 |
Metanephrine.free/Creatinine |
SRto |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Metanephrine Free/Creatinine [Molar ratio] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
umol/mol |
|
|
|
|
|
|
CHEM |
|
101177-4 |
|
|
|
|
Both |
|
|
|
0 |
Metaneph Free/Creat SerPl-sRto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; FR; Metaneph; Metaneph Free; Metanephrne; Metenephrine; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Scrto; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration ratio; Substance ratio; Unconjugated metanephrine |
2.75 |
2.74 |
|
|
|
|
|
|
|
umol/mol |
|
|
|
0 |
| 101178-2 |
Pneumocystis jirovecii DNA |
ThreshNum |
Respiratory System Specimen |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
Pneumocystis jirovecii DNA [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection |
|
NAM |
DefinitionDescription |
|
|
Ct |
|
|
|
|
|
|
MICRO |
|
101178-2 |
|
Probe.amp.tar |
|
|
Observation |
|
|
|
0 |
P jirovecii DNA Ct Resp Qn NAA+probe |
|
|
|
N |
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Breathing; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Lungs; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; P carinii; P jiroveci; P jirovecii; PCP; PCR; Pneumocystis carinii; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; RS; SDA; Spec; Strand Displacement Amplification; TMA; Transcription mediated amplification |
2.79 |
2.74 |
|
|
|
|
|
|
|
{Ct_value} |
|
|
Release 2.79: COMPONENT: Correcting typo in Jirovecii; Release 2.75: SYSTEM: There are 2 similar system's in LOINC: 1- Respiratory system 2- Respiratory specimen Due to an applied logic, the display in the System axis for 1 is Respiratory (adjective) without specification of sample, specimen, or other specific noun, while 2 is displayed fully as Respiratory specimen. Therefore for now we replaced 1 with Respiratory system specimen, which will affect 83 term. The result is replacing "Respiratory" with "Respiratory system specimen". This is the short approach. The bigger project is to potentially merge data that has either 1 or 2 together. This is a project to pass by the laboratory committee and will involve about 1500 concepts.; |
0 |
| 101179-0 |
Immunoglobulin light chains.free/Protein.total |
MFr |
Urine |
24H |
Qn |
|
|
ACTIVE |
Immunoglobulin light chains.free/Protein.total in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
% |
|
|
|
|
|
|
CHEM |
|
101179-0 |
|
|
|
|
Both |
|
|
|
0 |
BJ Protein Free 24h MFr Ur |
|
|
|
N |
|
1 day; 24 hours; 24HR; Bence Jones protein; BJ Protein; BJ Protein Free; BJP; Chain; Chemistry; FLC; FR; Immune globulin; Immuno; Immunoglob; Immunoglobin; Imunoglbon; Imunoglobn; Mass fraction; Non-protein bound; Percent; PR; Prot; QNT; Quan; Quant; Quantitative; Tot; Totl; TP; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
% |
|
|
|
0 |
| 10118-8 |
ST wave displacement.mid.lead AVF |
Elpot |
Heart |
Pt |
Qn |
EKG |
|
ACTIVE |
ST wave mid displacement in lead AVF |
|
MIN |
DefinitionDescription |
|
|
mV |
|
|
|
|
|
|
EKG.MEAS |
|
10118-8 |
|
EKG |
|
|
Observation |
|
|
|
0 |
ST wave MD L-AVF |
|
|
|
Y |
|
Cardiac; Cardio; Cardiology; ECG; EKG.MEASUREMENTS; Eklund; Electrical potential; Electrocardiogram; Electrocardiograph; Heart Disease; Hrt; Painter's colic; PB; Plumbism; Point in time; QNT; Quan; Quant; Quantitative; Random; ST wave MD L-AVF; Voltage |
2.48 |
1.0i |
|
|
|
|
|
|
|
mV |
|
|
|
0 |
| 101180-8 |
2-methyl AP-237 |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
2-methyl AP-237 [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101180-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
2-methyl AP-237 Ur Ql Cfm |
|
|
|
N |
|
2-methyl Bucinnazine; Anterio-Posterior; Anteroposterior; CAS 98608-61-8; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; hydrochloride salt 98608-59-4; II; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101181-6 |
MDMB-4en-PINACA |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
MDMB-4en-PINACA [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101181-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
MDMB-4en-PINACA Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101182-4 |
MDMB-4en-PINACA/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
MDMB-4en-PINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
101182-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
MDMB-4en-PINACA/Creat Ur Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/g{creat} |
|
|
|
0 |
| 101183-2 |
MDMB-4en-PINACA |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
MDMB-4en-PINACA [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101183-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
MDMB-4en-PINACA Ur Ql Cfm |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101184-0 |
4F-MDMB-BINACA |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
4F-MDMB-BINACA [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101184-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
4F-MDMB-BINACA Ur Cfm-mCnc |
|
|
|
N |
|
4F-ADB; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101185-7 |
4F-MDMB-BINACA/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
4F-MDMB-BINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
101185-7 |
|
Confirm |
|
|
Both |
|
|
|
0 |
4F-MDMB-BINACA/Creat Ur Cfm |
|
|
|
N |
|
4F-ADB; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mg{creat} |
|
|
|
0 |
| 101186-5 |
4F-MDMB-BINACA |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
4F-MDMB-BINACA [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101186-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
4F-MDMB-BINACA Ur Ql Cfm |
|
|
|
N |
|
4F-ADB; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 101187-3 |
ADB-BUTINACA |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
ADB-BUTINACA [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
101187-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
ADB-BUTINACA Ur Cfm-mCnc |
|
|
|
N |
|
ADB-BINACA; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; K2/SPICE; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 101188-1 |
ADB-BUTINACA/Creatinine |
MRto |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
ADB-BUTINACA/Creatinine [Mass Ratio] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mg creatinine |
|
|
|
|
|
|
DRUG/TOX |
|
101188-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
ADB-BUTINACA/Creat Ur Cfm |
|
|
|
N |
|
ADB-BINACA; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; CR; Crea; Creat; DRUG/TOXICOLOGY; Drugs; GCMS; K2/SPICE; LC/MS/MS; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UCr; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
ng/mg{creat} |
|
|
|
0 |
| 101189-9 |
ADB-BUTINACA |
PrThr |
Urine |
Pt |
Ord |
Confirm |
|
ACTIVE |
ADB-BUTINACA [Presence] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
101189-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
ADB-BUTINACA Ur Ql Cfm |
|
|
|
N |
|
ADB-BINACA; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; GCMS; K2/SPICE; LC/MS/MS; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.75 |
2.74 |
|
|
|
|
|
|
|
|
|
|
|
0 |
